ASSESSING THE COSTS AND BENEFITS OF MEDICAL-RESEARCH - THE DIABETIC-RETINOPATHY STUDY
ASSESSING THE COSTS AND BENEFITS OF MEDICAL-RESEARCH - THE DIABETIC-RETINOPATHY STUDY
复制标题
DOI：
10.1016/0277-9536(92)90128-d
复制
发表时间：
1992-05-01
影响因子：
5.4
通讯作者：
FERRIS, FL
中科院分区：
文献类型：
--
作者：
DRUMMOND, MF;DAVIES, LM;FERRIS, FL
大量稀缺资源被投入到医学研究中，但很少有人试图评估这些投资对社会的好处是否超过了成本。一种进行这种评估的方法已经开发出来，并被追溯应用于糖尿病视网膜病变研究，这是一项由美国国家眼科研究所在1972-1981年间资助的重大临床试验。据估计，这项试验耗资1050万美元，为社会净节省2.816亿美元(不包括生产损失的成本)(1982年的价格)，并为患者带来27.9万个视力年的收益。这种方法可以结合传统标准，如提案的科学价值和研究人员的能力，前瞻性地应用于考虑医学研究的优先事项。影响医学研究经济回报的主要因素是有关疾病的发病率、发病率和经济负担、有关医疗干预的成本和效果、临床试验对临床实践的可能影响，以及在试验期间获得的知识可能带来的好处的时间跨度。
Significant amounts of scarce resources are devoted to medical research, but there have been few attempts to assess whether the benefits to society of these investments exceed the costs. A method for undertaking such an assessment has been developed and applied retrospectively to the Diabetic Retinopathy Study, a major clinical trial funded by the National Eye Institute from 1972-1981. It was estimated that the trial, which cost $10.5 million, generated a net saving of $2816 million to society ($231 million when the costs of lost production are excluded) (1982 prices) and a gain to patients of 279,000 vision years. This approach could be applied prospectively in considering priorities for medical research, in conjunction with traditional criteria such as the scientific merit of the proposal and the capabilities of the investigators. The key factors affecting the economic returns from medical research are the prevalence, incidence and economic burden of the disease in question, the costs and effectiveness of the medical intervention concerned, the likely impact of the clinical trial on clinical practice and the likely timespan of benefits from knowledge obtained during the trial.